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Abstract - The 67 kDa laminin receptor (67LR) 
is a non-integrin cell surface receptor for laminin 
(LM) that derives from a 37 kDa precursor (37LRP). 
67LR expression is increased in neoplastic cells and 
correlates with an enhanced invasive and metastatic 
potentialin many human solid tumors, 
recommending this receptor as a new promising 
target for cancer therapy. This is supported by in 
vivo studies showing that 67LR downregulation 
reduces tumour cell proliferation and tumour 
formation by inducing apoptosis. 67LR association 
with the anti-apoptotic protein PED/PEA-15 
activates a signal transduction pathway, leading to 
cell proliferation and resistance to apoptosis. 
However, the main function of 67LR is to 
enhance tumor cell adhesion to the LM of basement 
membranes and cell migration, two crucial events in 
the metastasis cascade.Thus, inhibition of 67LR 
binding to LM has been proved to be a feasible 
approach to block metastatic cancer cell spread.  
Despite accumulating evidences on 67LR 
overexpression in hematologic malignancies, 67LR 
role in these diseases has not been clearly defined. 
Here, we review 67LR expression and function in 
normal and malignant hematopoietic cells, 67LR role 
and prognostic impact in hematological malignancies 
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 The 67kDa laminin receptor (67LR) is a non 
integrin cell surface receptor for extracellular matrix 
(ECM) able to bind with high affinity laminin-1 (LM), the 
major glycoprotein of basement membranes [1]. The 
primary function of 67LR is to promote tumor cell 
adhesion and migration to LM, crucial steps in tissue 
invasion and metastasis, by binding LM with high affinity 
(Kd=2x10-9 M). cDNA clones coding for human and 
mouse 67LR encode a protein with a molecular weight of 
32kDa and an apparent electrophoretic mobility of about 
37kDa. This polypeptide was identified as the precursor of 
67LR, and named 37kDa laminin receptor precursor 
(37LRP) [2].  
The mechanism by which 37LRP is converted 
into the mature 67LR is still unclear [3,4]. 37LRP is 
abundantly localized in the cytoplasm, where it acts as a 
multifunctional protein involved in the translational 
machinery and in ribosome assembly, and in the nucleus, 
tightly associated with nuclear structures [5].67LR, the 
mature form of the receptor, is localized in the cell 
membrane, from which it is internalized via early-
endosomes and lysosomal-mediated degradation [6]. On 
the cell surface, 67LR is able to interact with α6β4 
integrin; both receptors are co-expressed and physically 
associated in a complex that recognize different sites on 
LM, increasing the affinity of the binding [7].  Upon 
binding 67LR, LM interacts more efficiently with 
integrins and becomes more sensitive to proteolytic 
enzymes, releasing fragments endowed with chemotactic 
activity [8]. Three regions of 37LRP/67LR are involved in 
LM binding: (i) repeated sequences (TWEDS) at the C-
terminal, (ii) a direct laminin binding region (aminoacids 
205-229) [9] and (iii) a heparan sulfate dependent LM 
binding region (amino acids 161-180), also called peptide 
G, and containing the palindromic sequence LMWWML, 
responsible for LM binding [10]. 
All the three LM-binding sites of the receptor 
bind the same minimal YIGSR region of the β1 chain of 
LM [11]. As a membrane receptor, 37LRP/67LR is also a 
receptor for viruses, bacteria and prions [5,12].67LR is 
overexpressed in neoplastic cells and correlates with an 
enhanced invasive and metastatic potential in many solid 
tumors [13-17]. 67LR role in metastatic diffusion is well 
documented and mostly rely in its  ability to mediate 
adhesion to the LM of basement membranes of epithelia 
and endothelia and to mediate trans-endothelial migration 
of metastatic cancer cells [18]. 67LR role in hematological 
malignancies has not been clearly defined, even though 
many reports have been produced on its expression, 
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II.  37LRP/67LR FUNCTION AND TARGETING IN 
SOLID TUMORS 
 
 Given its importance in solid tumor progression, 
67LR represents a suitable target for cancer therapy and 
different approaches have been used to inhibit its function, 
in order to contribute to metastasis prevention and/or 
treatment (reviewed in 19).Different strategies used 
against this receptor were able to reduce the invasive 
potential of HT1080 fibrosarcoma cells [20]. 
37LRP/67LR is able to affect tumor progression also by 
promoting angiogenesis; indeed,  a receptor specific 
antibody inhibited endothelial tube formation 
[21].37LRP/67LR is involved in the maintenance of 
cellular viability and reduction of its expression induced 
apoptosis of cancer cells [22]. The role of 37LRP/67LR in 
apoptosis was also confirmed by the finding by our group 
of a structural and functional association between 67LR 
and the anti-apoptotic protein PED/PEA-15 [23]. 
A recent study reveals a novel function of 
37LRP/67LR: siRNA treatment of 37LRP/67LR resulted 
in a significant decrease of telomerase activity 
[24].Recently, our group searched, by a virtual screening 
(VS) approach, small molecules able to specifically target 
67LR. VS is a computational method that allows the 
identification of new therapeutics for a specific biological 
target from large chemical libraries [25]. This study led to 
the identification of a specific inhibitor of 37LRP/67LR, 
NSC47924. This compound specifically inhibited cell 
adhesion and migration to LM, as well as cell invasion. A 
subsequent hierarchical similarity search with NSC47924 
allowed the refinement of this lead compound, identifying 
additional four compounds able to inhibit cell binding to 
LM and to block in vitro cancer cell invasion, exhibiting a 
lower Ic50 as compared to NSC47924 [26].  
These small molecules are cell-permeable and 
orally available, the most important advantage in respect 
to monoclonal antibodies. Moreover, they showed a short 
half-life, high specificity and low toxicity, thus may be of 
considerable clinical benefit in tailoring personalized 
target therapies in cancer. 
 
 
III.  37LRP/67LR EXPRESSION AND FUNCTION IN 
NORMAL HEMATOPOIETIC STEM CELLS 
 
HSCs normally resides within the bone marrow 
(BM) and can be mobilized into the circulation by 
chemotherapy or cytokine treatment [27]. The most 
common mobilizer is the granulocyte-colony stimulating 
factor (G-CSF). GCSF-mobilized HSCs are increasingly 
used in stem cell transplantation (SCT) for the relative 
ease of collection, the higher yield and the shorter time to 
engraftment than BM stem cells [28].  
We have demonstrated that 67LR expression is 
increased in G-CSF-mobilized HSCs, as compared with 
BM HSCs, and significantly correlated with mobilization 
efficiency [29]. During G-CSF–induced HSC 
mobilization, the expression of laminin receptors switched 
from α6 integrins, which mediated LM-dependent 
adhesion of steady-state human BM HSCs, to 67LR, 
responsible for G-CSF–mobilized HSC migration toward 
LM. This switch in the expression of LM receptors also 
induced a change in the signal transduction pathway 
activated in response to LM binding. In vitro G-CSF 
treatment, alone or combined with exposure to marrow-
derived endothelial cells, induced 67LR up-regulation in 
marrow HSCs; moreover, anti-67LR antibodies 
significantly inhibited transendothelial migration of G-
CSF–stimulated marrow HSCs. Finally, G-CSF–induced 
mobilization in mice was associated with 67LR up-
regulation both in circulating and marrow HSCs, and anti-
67LR antibodies significantly reduced HSC mobilization.  
Engraftment of HSCs to BM after transplantation 
is a key factor in SCT. G-CSF-induced 67LR 
overexpression on G-CSF mobilized HSCs, could play a 
crucial role also in HSC homing back to BM by mediating 
interactions with the basement membranes of vascular 
endothelia and subsequent cell migration. Indeed, 67LR 
also promoted homing to BM of transplanted HSCs, 
playing a key role in erythroid progenitor and precursor 
cells lodgment within the BM [30]. Thus, 67LR 
overexpression occurs in BM and circulating normal 
HSCs after cytokine stimulation and regulates HSC 
trafficking from and to BM. These findings further 
support a model in which HSC mobilization could 
represent a physiologic counterpart of leukemic and 
metastatic cell spread. 
 
 
IV. 37LRP/67LR EXPRESSION AND TARGETING IN 
CHRONIC LYMPHATIC LEUKEMIA 
 
B-cell chronic lymphocytic leukemia (CLL) is a 
heterogeneous group of diseases with various B-cell 
membrane markers expression and clinical course [31]. 
Despite the identification of genetic and phenotypic 
markers that correlate with prognosis, the biological basis 
of this clinical variability remains unclear [32].  
In CLL, 37LRP/67LR is widely expressed and 
37LRP is considered as an oncofetal antigen (OFA), thus 
often referred to as OFA/iLRP (oncofetal 
antigen/immature laminin receptor) [33]. Oncofetal 
antigens are conserved tumor-associated antigens or 
transplantation antigens expressed on the surface of 
human tumors and on fetal cells but not on normal adult 
tissues. OFAs are able to induce an immune response 
against tumors as well as a tolerogenic response, linked to 
cancer progression [34].Dendritic cells (DCs) primed with 
OFA/iLRP or transfected with RNAs specific to 
OFA/iLRP induced a T-cell immune response against 
hematological malignancies, in particular acute myeloid 
leukemia (AML) and chronic lymphatic leukemia (CLL) 
cells. In a murine B-cell lymphoma model, treatment with 
syngeneic DCs transfected with OFA/iLRP-coding RNA 
resulted in powerful antitumor effect [35]. There is also 
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evidence of a humoral response against OFA/iLRP: pre-
existing antibodies (Abs) to OFA/iLRP have been 
 
Figure 1. 67LR involvement in hematopoietic stem cell 
(HSC) mobilization. 
Panel A. Steady-state interactions between HSCs and LM of the BM 
microenvironment are mediated by α6 containing integrin receptors 
transducing proliferative signals. Panel B. G-SCF modification of HSC 
ECM receptor profile leads to α6 integrin downregulation and 67LR 
overexpression. Panel C. Overexpressed 67LR, through LM binding, 
transduces motility signals, stimulates the secretion of proteolytic 
enzymes, modifies LM structure with the release of motility  fragments. 
Panel D. 67LR engagement by LM enhances HSC release from the BM; 
mobilized HSCs show increased 67LR expression important for their 
subsequent homing to BM. 
detected in sera of CLL patients. Patient Abs to 
OFA/iLRP were cytotoxic in vitro and individuals with an 
anti-OFA/iLRP humoral response had a more favorable 
prognosis. OFA/iLR Abs were cytotoxic and exerted also 
a role in the graft-vs-leukemia effect in CLL [36].  
Confirming its nature of immune stimulating 
tumor associated antigen, high expression of the protein 
OFA/iLR correlated with mutated IGVH status and 
predicted for a favorable prognosis in CLL [37]. These 
results are in agreement with reports on the ability of anti -
37LRP/67LR monoclonal antibodies (MoAbs) to block 
neoplastic B cell proliferation in vitro and in vivo. Two 
MoAbs, BV-15 and BV-27, showed anti-metastatic 
activity in the A20 B-cell leukemia model. Only BV-27 
was growth-suppressive in vitro; however, both antibodies 
suppressed A20 cell attachment to LM [38]. Thus, 
inhibition of LM attachment seems crucial for the 
inhibitory effect, as reported with antibodies targeting 
both the immature and mature forms of the receptor or 
with treatments that down-regulate the expression of 
37LRP/67LR in solid tumors [19,39]. These MoAbs could 
be used therapeutically even though it is not clear whether 
they exert their action by effector functions (Ab or 
complement dependent cytotoxicity) or by their action 
(cell growth inhibition and/or blocking of cell binding to 
LM). 
Epigallocatechin-3-gallate (EGCG) is the major 
polyphenol of green tea; it is a small molecule that 
functions as an antitumor and antiangiogenic agent. 
EGCG induces cell death and cell cycle arrest and 67LR 
was identified as a receptor able to mediate its anti-cancer 
activity [40]. In contrast with previous results showing 
that 67LR inhibition, through MoAbs, blocked neoplastic 
B lymphocyte proliferation, a phase II clinical trial 
demonstrated that 67LR stimulation by oral 
PolyphenonETM was well tolerated and 29 of 43 CLL 
patients (67%) showed evidence of a biological response 
with decreased lymphadenopathy and/or absolute 
lymphocyte count [41]. Moreover, there was a significant 
correlation between EGCG susceptibility and 67LR 
expression in CLL cells and Vardenafil, a clinically 
available phosphodiesterase inhibitor, potentiated the 
killing effect of EGCG on CLL cells [42]. The molecular 
mechanism of Vardenafil action on EGCG-induced 67LR 
stimulation and tumor cell killing was better elucidated in 
multiple myeloma cells (see below). 
 
 
V. 37LRP/67LR EXPRESSION AND FUNCTION IN 
MULTIPLE MYELOMA 
 
Multiple myeloma (MM) represents a B cell 
malignancy, characterized by a monoclonal proliferation 
of malignant plasma cells. During disease evolution, 
terminally differentiated B cells preferentially accumulate 
in the BM. LN stimulated in vitro migration of human and 
murine MM cells, through its binding to 67LR, 
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overexpressed on MM cells. 67LR inhibition by the LM-
derived peptide CDPGYIGSR, resulted in a decreased 
homing of MM cells to the BM in a murine in vivo model 
[43]. Thus, LM acts as a chemoattractant for MM cells by 
interaction with 67LR and this interaction might be 
important during the trafficking of MM cells, as already 
demonstrated for normal HSCs [29,30]. 67LR is also 
involved in lymphoma cells homing to lymph nodes and 
in their trafficking to specific organs [44].  
In MM, EGCG was able to induce inhibition of 
cell growth and apoptosis in vitro and in vivo. Silencing of 
67LR resulted in abrogation of EGCG-induced apoptosis, 
confirming the role of 67LR in EGCG-mediated growth 
inhibition in MM cells [45].EGCG induced apoptosis 
through 67LR be determining phosphorylation of PKCδ 
and activation of acid sphingomyelinase (aSMase). cGMP 
is a critical mediator of 67LR-dependent PKCδ/aSMase 
activation and MM apoptosis. EGCG induces nitric oxide 
(NO) production through 67LR-dependent activation of 
Akt and endothelial nitric oxide synthase (eNOS). NO 
increases the intracellular level of cGMP, that induces 
apoptosis by activating PKCδ/aSMase pathway. aSMAse 
acts on sphingomyelin [46] to generate ceramide, which 
induced lipid-rafts clustering, critical for apoptosis. Orally 
administered EGCG activated PKCδ and aSMase in a 
murine MM xenograft model [47].In MM cells, 
phosphodiesterase 5 (PDE5), a major negative regulator of 
cGMP, is overexpressed and is able to reduce 67LR-
mediated apoptosis induced by EGCG. Thus, Vardenafil, 
a PDE5 inhibitor, induced an enhancement of the EGCG-
activated 67LR-dependent apoptosis, through 
amplification of the downstream effectors PKCδ and 
aSMase, and prolongation of the survival time in a mouse 
xenograft model [46,47].  
 
 
VI. 37LRP/67LR EXPRESSION AND FUNCTION IN 
ACUTE MYELOID LEUKEMIA 
 
Acute myeloid leukaemia (AML) is an 
aggressive blood cancer caused by the proliferation of 
immature myeloid cells. The genetic abnormalities 
underlying AML affect signal transduction pathways, 
transcription factors and epigenetic modifiers. The genetic 
landscape of AML cells could exert a direct effect on the 
anti-leukemic immune responses [48]. Thus, 67LR 
expression and function in AML could play a critical role 
in the evolution and prognosis of the disease. 
We detected enhanced 67LR expression in 40% 
of 53 de novo AMLs, which frequently exhibited 
monocytic or myelomonocytic morphology. We did not 
detect 67LR expression in normal BM hematopoietic 
cells, in precursor-B acute lymphoblastic leukemia, in 
chronic lymphocytic leukemia, or in chronic myeloid 
leukemia in chronic phase. 67LR overexpression 
corresponded to a higher adhesion to LM. In contrast with 
67LR behavior in solid tumors, no statistically significant 
difference was found between 67LR expression and any 
hematological characteristic of the disease at diagnosis, 
nor between 67LR expression and outcome of the disease 
as measured by complete remission rate, disease-free 
survival, or overall survival [49].  
A more recent study demonstrated 67LR 
expression influenced the characteristics of AML cells 
toward an aggressive phenotype and increased the 
expression of GM-CSF receptor. Indeed, increased 
expression of 67LR was significantly related to elevation 
of white blood cell count, lactate dehydrogenase, and 
poorer survival among AML patients. Forced expression 
of 37LRP/67LR enhanced proliferation, cell-cycle 
progression, and antiapoptosis of AML cells associated 
with phosphorylation of STAT5, in the absence of 
stimulation LM. There was a significant relationship 
between the expression of 67LR and GM-CSFR in acute 
myeloid leukemia samples, with enhanced GM-CSFR 
signaling [50].  
This observation is not surprising; indeed, a 
previous work showed that 67LR was an interacting 
protein of both the alpha and beta subunits of GM-CSFR. 
Whereas GM-CSF functions by engaging the alpha and 
beta subunits into receptor complexes, 67LR inhibited 
GM-CSF-induced receptor complex formation. 67LR 
engagement by LM relieved the LR inhibition of GM-
CSFR. These findings provided a mechanistic basis for 
enhancing host defense cell responsiveness to GM-CSF at 
transendothelial migration sites, where 67LR is engaged 
by LM,  while suppressing it in circulation [51].  
EGCG-induced cell death through cGMP/aSMase axis 
activation and lipid raft clustering was described also in 





Mobilization of HSCs into the blood following 
treatment with chemotherapy or cytokines mimics the 
enhancement of the physiologic stem-cell release in 
response to stress and inflammatory signals and results 
from changes in the adhesion profile of HSCs, facilitating 
their egress from BM. Cytokine-stimulated HSCs, 
leukemia and multiple myeloma cells, as metastatic cells 
from solid tumors, activate a 67LR-derived signaling 
pathway, which leads to cell dissemination and trafficking 
through the host. 
36LRP/67LR is overexpressed in CLL and AML, 
but with a different prognostic impact. 37LRP/67LR 
overexpression in CLL has a positive impact, due the 
stimulation of an anti-leukemia effect. The same effect is 
not observed in AMLs in which 67LR upregulation  is 
correlated, as in solid tumors, to increased aggressiveness 
and poorer response to treatments.  
Biological agents inhibiting 67LR binding to LM, 
such as antibodies and peptides, could represent an 
efficient tool to target CLL and myeloma cells and  the 
activity of EGCG in CLL has been already proved by an 
early clinical trial. Concurrently, many reports indicate 
that EGCG activity through 67LR may help in the design 
of new strategies to also treat AML and MM. 
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It is intriguing that a 67LR stimulating small 
molecule, such as EGCG, can exert the same antitumor 
effect of 67LR inhibitory molecules. Most probably, 
clarification of the molecular mechanism of action of new 
small molecules inhibiting LM binding to  67LR, such as 
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